The Latest Breaking News from Lilly

New data from an experimental drug being developed by Eli Lilly & Co. raises an intriguing question about obesity treatments: How low can the weight loss go?

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

Eli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

Tirzepatide could be given to patients with diabetes or heat disease

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

From classic cars to 4WD utes, Noah Wasmer wants EV conversions to become mainstream.

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.